We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LDO:MILLeonardo SpA Analysis

Data as of 2026-03-10 - not real-time

€62.56

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Leonardo is trading well above its 20‑day and 50‑day moving averages, with the RSI sitting comfortably in the 60s and a bullish MACD histogram confirming upward momentum. Volume is increasing, supporting the technical upside, and the price remains near the upper end of its 52‑week range, just below the recent resistance level. The company posted solid top‑line growth of roughly 10% YoY and maintains healthy operating margins, while free cash flow remains positive and the dividend payout ratio is modest at about 26%, indicating dividend sustainability. However, the discounted cash‑flow model values the stock at roughly half its current market price, flagging a significant overvaluation relative to intrinsic fundamentals. Analyst consensus remains bullish with a “buy” recommendation, but the gap between market price and fair value suggests caution.
From a risk perspective, the stock exhibits high 30‑day volatility yet a low beta, reflecting limited market‑wide price swings but pronounced intra‑sector swings. The aerospace & defense sector carries medium regulatory and geographic exposure, given its reliance on government contracts across Europe and the United States. Overall, while short‑term technicals are favorable, the valuation gap and sector risks temper enthusiasm, making a nuanced, risk‑adjusted stance advisable.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish technical indicators (price above SMAs, bullish MACD)
  • Increasing volume supporting momentum
  • Significant overvaluation relative to DCF fair value

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Steady revenue growth and solid cash flow generation
  • Sustainable dividend with low payout ratio
  • Valuation still above intrinsic estimates, limiting upside

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Persistent overvaluation may lead to price correction
  • High sector volatility and regulatory exposure
  • Fundamentals support a fair value far below current price

Key Metrics & Analysis

Financial Health

Revenue Growth10.60%
Profit Margin5.54%
P/E Ratio31.1
ROE11.76%
ROA4.43%
Debt/Equity41.26
P/B Ratio4.0
Op. Cash Flow€1.6B
Free Cash Flow€887.1M
Industry P/E29.6

Technical Analysis

TrendBullish
RSI63.6
Support€52.42
Resistance€62.92
MA 20€57.64
MA 50€56.72
MA 200€51.11
MACDBullish
VolumeIncreasing
Fear & Greed Index80.45

Valuation

Fair Value€28.77
Target Price€62.52
Upside/Downside-0.07%
GradeOvervalued
TypeBlend
Dividend Yield0.83%

Risk Assessment

Beta0.43
Volatility44.01%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.